share_log
Benzinga ·  May 2 07:45
Organogenesis Shares Are Trading Higher After the Company Announced That Its Phase 3 Randomized Control Trial Evaluating the Safety and Efficacy of ReNu Achieved Its Primary Endpoint
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment